The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies
- 31 December 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27, S88-S91
- https://doi.org/10.1016/0277-5379(91)90586-3
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.Journal of Clinical Oncology, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- New Approaches to the Immunotherapy of Cancer Using Interleukin-2Annals of Internal Medicine, 1988
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1JNCI Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Interferon therapy in disseminated renal cell carcinomaRadiotherapy and Oncology, 1985